Navigation Links
New therapies increase survival rates in post-transplant liver cancer patients
Date:3/25/2010

A recent study found that sirolimus-based immunosuppression following liver transplantation in patients with non-resectable hepatocellular carcinoma (liver cancer) significantly increases survival rates for this patient population. Results of this study appear in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

According to the NIH, hepatocellular carcinoma (HCC) is a common type of liver cancer, and one of the few cancers in the U.S. in which the number of new cases is expected to rise over the next two decades. Liver transplantation is an important treatment option for selected patients with non-resectable HCC, but the ideal immunosuppression protocol is still a matter of debate. To date, no single protocol has gained widespread acceptance.

Researchers at the University of Alberta led by Dr. Christian Toso set out to define the immunosuppressant regimen associated with the best survival after liver transplantation for HCC. This study was not designed to look at the effect of specific drugs, but at protocols containing specific drugs. Based on data from the Scientific Registry of Transplant Recipients, the researchers evaluated 2491 adult recipients of isolated liver transplantation for HCC and 12167 for non-HCC diagnoses between March 2002 and March 2009. All patients remained on stable maintenance immunosuppression protocols for at least six months post-transplant. The unique outcome variable of the study was patient survival; all deaths were taken into account in the analysis whether they were associated with HCC or not.

In a multivariate analysis, only anti-CD25 antibody induction and sirolimus-based maintenance therapy were associated with improved survivals after transplantation for HCC. The other studied drugs, including calcineurin-inhibitors, did not demonstrate a significant impact. To determine whether the observed
'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Study evaluates costs and benefits associated with new colon cancer therapies
2. Intense Cholesterol, Blood Pressure Therapies Dont Help Type 2 Diabetics
3. ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes
4. NIH/NHLBI-funded PACT Group Announces the Renewal of Production Assistance for Cellular Therapies (PACT)
5. ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
6. Notch-blocking drugs kill brain cancer stem cells, yet multiple therapies may be needed
7. MSU researcher linking breast cancer patients with alternative therapies
8. Translational Regenerative Medicine Forum sets stage for accelerating therapies to patients
9. Kids Use of Alternative Therapies Often Mimics Parents
10. Med students say conventional medicine would benefit by integrating alternative therapies
11. China a rising star in regenerative medicine despite world skepticism of stem cell therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Bethesda, MD (PRWEB) February 27, 2015 ... Foundation (Meso Foundation) and the National Cancer Institute ... Malignant Mesothelioma at the National Institutes of Health ... parts: one part is dedicated to medical professionals ... other is directed to the general public, including ...
(Date:2/27/2015)... Hills, CA (PRWEB) February 27, 2015 ... been chosen as their Sage ERP Document Management Partner ... Sage 300 ERP, Sage CRM and other complimentary solutions ... Global have worked side-by-side for many years to provide ... Sage ERP applications. , “We are thrilled to ...
(Date:2/27/2015)... NY (PRWEB) February 27, 2015 In ... to the community by providing free dental care from ... has partnered with Dentistry from the Heart, and ... 11, 2015. The first 50 patients who are in ... they can’t afford, will have access to high­quality service ...
(Date:2/27/2015)... February 27, 2015 The federal court ... that allege use of the statin medication can increase ... issued a new order pertaining discovery in the cases ... Liebhard LLP comments. The Order, which was issued in ... February 25th, directs the parties to schedule certain witness ...
(Date:2/27/2015)... 2015 According to court documents, Donna ... June 25, 2013 and underwent a procedure during which ... mouth. Because the duodenoscope allegedly had not been ... “superbug” carbapenem-resistant Enterobacteriaceae (CRE). , A lawsuit ... County on behalf of Ms. Pirolli alleging that Lutheran ...
Breaking Medicine News(10 mins):Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3Health News:Altec Announces 2014 Sage ERP Document Management Partner of the Year Award Recipient 2Health News:Dr. Umanoff Unites with Dentistry from the Heart to Provide Community with Charitable Dental Care 2Health News:Dr. Umanoff Unites with Dentistry from the Heart to Provide Community with Charitable Dental Care 3Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 2Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 3Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2
... , Survey Measures Impact of Recession on Healthcare Use by ... Twenty-five percent of Americans say they had difficulty ... Baby Boomer and Generation X age groups leading the way, ... study, which tracks the impact of the recession on consumers, ...
... ... announces the launch of an anonymous, confidential survey to determine the extent of drowsy ... and Ship Captains. , ... New York, NY (Vocus) June 22, 2009 -- Snoring Isn,t Sexy ® ...
... , , BIRMINGHAM, England, June 21 ... June at the Rotary International Convention to recognize the humanitarian service ... work in support of the UN Millennium Development Goals. , ... , , Ban,s remarks are scheduled for the plenary session ...
... (ICD) have an ongoing risk of sudden incapacitation that ... Driving restrictions are imposed making these recommendations an ... recommendations for drivers with ICD,s was presented at a ... Germany on Sunday 21 June. A team ...
... proposal would be devastating to frail elderly and disabled ... The Ohio Skilled Nursing Care Coalition, consisting of the ... care for more than 80,000 frail elderly and disabled ... Governor Ted Strickland announced late Friday. , , ...
... experts stress that men shouldn,t take them with just this ... over-the-counter painkillers such as aspirin and ibuprofen might help men ... quick to caution men not to self-dose or to take ... side effects can result. , "Our data suggest if men ...
Cached Medicine News:Health News:Thomson Reuters Study Finds Baby Boomers and Generation X Face Healthcare Cost Hurdles 2Health News:Thomson Reuters Study Finds Baby Boomers and Generation X Face Healthcare Cost Hurdles 3Health News:Snoring Isn't Sexy, LLC Launches Survey to Determine Extent of Drowsy Drivers on Land, Sea and In The Air 2Health News:United Nations Secretary-General Ban Ki-moon to Keynote Rotary International's 100th Annual Meeting 2Health News:United Nations Secretary-General Ban Ki-moon to Keynote Rotary International's 100th Annual Meeting 3Health News:Implanted defibrillators: New recommendations for drivers with ICDs 2Health News:Painkillers May Be Good for the Prostate 2Health News:Painkillers May Be Good for the Prostate 3
(Date:2/27/2015)... VANCOUVER, Canada and HOUSTON, TX ... ("ESSA" or the "Company") (TSX-V: EPI) and Bloom Burton ... have released from voluntary contractual lock-up (the "Lock-Up") 2,353,130 ... of the Common Shares originally subject to the Lock-Up. ... shares will be free trading immediately upon release from ...
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma Corp. ... biopharmaceutical company developing therapeutic products for rare diseases, ... the European Organisation for Rare Diseases™ (EURORDIS™), The ... in observing Rare Disease Day. On ... organizations, industry, and other participants conduct special events ...
(Date:2/27/2015)... , Feb. 27, 2015  Organovo Holdings, Inc. ... focused on delivering breakthrough 3D bioprinting technology, announced ... Chief Executive Officer, will present live at VirtualInvestorConferences.com ... you to join us for this Company update," ... on our commercial launch of the exVive3D Liver, ...
Breaking Medicine Technology:ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4
... Inc. (Pink Sheets:  TROV.PK), a developer of transrenal ... as head of commercial operations, effective April 16, ... diagnostic sales, marketing and operational experience. Most recently, ... at bioTheranostics, Inc.  McCormick served as a member ...
...  Faruqi & Faruqi, LLP, a leading national securities ... Chelsea Therapeutics International, Ltd. ("Chelsea" or the "Company") ... ) The investigation focuses ... federal securities laws by failing to disclose that: ...
Cached Medicine Technology:Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations 2Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm 2
... FalciVax is a two site ... for the detection of P. ... (Pf. HRP-2) and P. vivax ... also be used for specific ...
Malaria Pf. Assay Range...
ADVANTAGE MALARIA STIX is a visual, rapid and sensitive immunoassay for the qualitative differential detection of P.falciparum (P.f) and P.vivax (P.v) malaria in Human Blood only....
Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)...
Medicine Products: